Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2022 Mar 31

PMID 35355504

Authors

Chien-Chih Chen

Toshiaki Nakano

Li-Wen Hsu

Chia Yi Chu

Kuang-Tzu Huang

Affiliations

Soon will be listed here.

Abstract

Background: Atypical antipsychotics such as olanzapine often cause metabolic side effects such as obesity and diabetes, leading to an increased risk of nonalcoholic fatty liver disease. The aim of the present study was to investigate the effects of olanzapine treatment on hepatic lipid metabolism and its possible relationship with adipose tissue status.

Methods: Using a female rat model, we investigated the effects of chronic olanzapine administration on the regulation of carbohydrate and lipid metabolism including lipid biosynthesis, oxidation, efflux, and lipolysis in liver and adipose tissue.

Results: The body weight, liver mass and visceral adiposity after olanzapine treatment (2 mg/kg) for five weeks were not significantly different compared with vehicle controls. The serum level of triglycerides was higher in the vehicle controls than in olanzapine-treated rats. Unexpectedly, olanzapine treatment did not reduce glucose tolerance in our model. The expression of functional thermogenic protein uncoupling protein 1 (UCP1) was increased in brown adipose tissue (BAT) of the olanzapine group. Additionally, olanzapine treatment also reduced adipose inflammation in white adipose tissue (WAT). The transcription factor sterol regulatory element-binding protein (SREBP)-1c, a key early regulator of lipogenesis, was downregulated following olanzapine treatment. The expression of genes related to the triglycerides synthesis apparatus in the liver was upregulated in the olanzapine group. Olanzapine treatment induced genes involved in PPAR-α signaling and mitochondrial fatty acid oxidation in response to increased ATGL-mediated lipolysis in the liver.

Conclusion: Together, our findings suggest a complicated link between olanzapine therapy and metabolic disturbance and may garner interest in assessing the action of antipsychotic-induced metabolic disturbances.

References

Smith J, Griffiths L, Band M, Horne D . Cardiometabolic Risk in First Episode Psychosis Patients. Front Endocrinol (Lausanne). 2020; 11:564240. PMC: 7732528. DOI: 10.3389/fendo.2020.564240. View

Lauressergues E, Staels B, Valeille K, Majd Z, Hum D, Duriez P . Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(5):427-39. DOI: 10.1007/s00210-010-0499-4. View

Horska K, Ruda-Kucerova J, Babinska Z, Karpisek M, Demlova R, Opatrilova R . Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats. Psychoneuroendocrinology. 2016; 73:177-185. DOI: 10.1016/j.psyneuen.2016.07.218. View

Cohen J, Perel J . Adolescent weight loss during treatment with olanzapine. J Child Adolesc Psychopharmacol. 2005; 14(4):617-20. DOI: 10.1089/cap.2004.14.617. View

Yang C, Wang Y, Lin S, Hong Y, Liao K, Hsieh S . Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats. Int J Mol Sci. 2019; 20(3). PMC: 6387243. DOI: 10.3390/ijms20030640. View

Tang S, Wu F, Lin X, Gui W, Zheng F, Li H . The Effects of New Selective PPAR Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism. J Diabetes Res. 2020; 2020:4179852. PMC: 7222497. DOI: 10.1155/2020/4179852. View

Sahpolat M, Ari M . Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey. Nord J Psychiatry. 2020; 75(1):73-78. DOI: 10.1080/08039488.2020.1815080. View

Rojo L, Gaspar P, Silva H, Risco L, Arena P, Cubillos-Robles K . Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol Res. 2015; 101:74-85. DOI: 10.1016/j.phrs.2015.07.022. View

Stefan N, Peter A, cegan A, Staiger H, Machann J, Schick F . Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia. 2008; 51(4):648-56. DOI: 10.1007/s00125-008-0938-7. View

10.

Ferno J, Ersland K, Duus I, Gonzalez-Garcia I, Fossan K, Berge R . Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. Eur Neuropsychopharmacol. 2015; 25(6):923-32. DOI: 10.1016/j.euroneuro.2015.03.002. View

11.

Li Y, Yun K, Mu R . A review on the biology and properties of adipose tissue macrophages involved in adipose tissue physiological and pathophysiological processes. Lipids Health Dis. 2020; 19(1):164. PMC: 7350193. DOI: 10.1186/s12944-020-01342-3. View

12.

Albaugh V, Henry C, Bello N, Hajnal A, Lynch S, Halle B . Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring). 2006; 14(1):36-51. PMC: 2761763. DOI: 10.1038/oby.2006.6. View

13.

Liu J, Chen N, Guo Y, Guan X, Wang J, Wang D . Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. J Psychiatr Res. 2021; 140:409-415. DOI: 10.1016/j.jpsychires.2021.06.001. View

14.

Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T . Attitudes toward metabolic adverse events among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat. 2016; 12:427-36. PMC: 4771408. DOI: 10.2147/NDT.S98711. View

15.

McNamara R, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton J . Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res. 2011; 129(1):66-73. PMC: 3100393. DOI: 10.1016/j.schres.2011.03.016. View

16.

Wu J, Wang S, Alvarez F, Casavant S, Gauthier N, Abed L . Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011; 54(1):122-32. DOI: 10.1002/hep.24338. View

17.

Shamshoum H, Medak K, Townsend L, Ashworth K, Bush N, Halm M . AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice. FASEB J. 2019; 33(12):14010-14021. DOI: 10.1096/fj.201901820R. View

18.

Milano W, De Rosa M, Milano L, Capasso A . Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome. Open Neurol J. 2013; 7:23-31. PMC: 3722531. DOI: 10.2174/1874205X01307010023. View

19.

Sahpolat M, Ari M, Hanifi Kokacya M . Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia. Clin Psychopharmacol Neurosci. 2020; 18(1):109-115. PMC: 7006973. DOI: 10.9758/cpn.2020.18.1.109. View

20.

Ong K, Mashek M, Davidson N, Mashek D . Hepatic ATGL mediates PPAR-α signaling and fatty acid channeling through an L-FABP independent mechanism. J Lipid Res. 2014; 55(5):808-15. PMC: 3995459. DOI: 10.1194/jlr.M039867. View